Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company. The Company is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The Company sells portfolio products consisting of promoted products and non-promoted products, which incorporate its Osmodex drug delivery system. The Company’s Osmodex drug delivery system uses osmotic pressure to provide a controlled drug release and is adaptable to many different combinations of immediate-release, extended-release and controlled- or delayed-release formulations that contain one or more drugs. The Company’s non-promoted product portfolio includes methylphenidate ER and venlafaxine extended-release tablets (VERT) as well as ANDAs and prescription dietary supplements. Its promoted products are led by Divigel and M-72 (methylphenidate hydrochloride extended-release tablets, 72 mg).